Product ID: SQSG35H2018
Global Biopharmaceutical CMO & CRO Market Size, Share, Growth Analysis, By Source(Mammalian, Non-mammalian), By Service(Contract Manufacturing (Process Development, Downstream), By Product(Biologics (Monoclonal antibodies (MAbs), Recombinant Proteins) - Industry Forecast 2024-2031
Report ID:
SQSG35H2018 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
102 |
Figures:
76
Global Biopharmaceutical CMO & CRO Market Regional Insights
North America had the greatest revenue share in 2021, accounting for almost 35% of overall sales. This might be attributed to the fact that there are several local service providers in the region. CMOs are in charge of producing a sizable portion of the authorised goods marketed in the United States. The creation of a number of small and mid-sized biopharmaceutical businesses (SMEs) that lack the capabilities and funds to build well-equipped facilities is troublesome. As a result, CMOs and SMEs in the United States have become increasingly dependent on one another, resulting in the United States market becoming the most dominating internationally.
The Asia Pacific region is expected to increase at a significant compound annual growth rate throughout the projection period. The key reason for the growth in outsourcing in Asian countries is cost-related benefits such as cheaper labour rates and operating costs throughout the region. This is the fundamental cause for the surge in Asian outsourcing. It is expected that India would see great development as a result of the massive quantity of big molecule manufacturing that takes place in the nation. The lack of worldwide regulatory standardisation for biosimilar product approval is a critical element driving the Indian industry ahead.
Global Biopharmaceutical CMO & CRO Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
